Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9)

  1. Pozzilli, P.
  2. Norwood, P.
  3. Jódar, E.
  4. Davies, M.J.
  5. Ivanyi, T.
  6. Jiang, H.
  7. Woodward, D.B.
  8. Milicevic, Z.
Journal:
Diabetes, Obesity and Metabolism

ISSN: 1463-1326,  1462-8902

Year of publication: 2017

Volume: 19

Issue: 7

Pages: 1024-1031

Type: Article

DOI: 10.1111/DOM.12937 GOOGLE SCHOLAR lock_openOpen access editor
Data source: Scopus